Diabetic nephropathy is characterized by an expansion of glomerular mesangium, caused by mesangial cell proliferation and excessive accumulation of extracellular matrix (ECM) proteins, which eventually leads to glomerulosclerosis and renal failure. Activator protein-1 (AP-1), a transcription factor, is implicated in the transcriptional regulation of a wide range of genes participating in cell proliferation and ECM production. This investigation was undertaken to test the hypothesis that AP-1 plays an important role in ECM gene expression, and to develop a molecular therapeutic strategy based on decoy oligodeoxynucleotides (ODN). In this report, we show that transfection with AP-1 decoy ODN strongly inhibits high glucose-and angiotensin II-induced cell proliferation and expression of ECM genes in cultured mesangial cells in vitro. Administration of AP-1 decoy ODN into streptozotocin-induced diabetic rat kidney in vivo using the hemagglutinating virus of Japan (HVJ)-liposome method virtually abolished TGF-b1 and plasminogen activator inhibitor-1 expression. Our results collectively indicate that AP-1 activation is crucial for mesangial cell proliferation and ECM production in response to high glucose and angiotensin II. Moreover, use of stable AP-1 decoy ODN combined with the highly effective HVJliposome method provides a novel potential molecular therapeutic strategy for the prevention of diabetic nephropathy. Gene Therapy (2004) 11, 916-923.
Introduction
Mesangial expansion, caused by mesangial cell (MC) proliferation and excessive accumulation of extracellular matrix (ECM) proteins, is a key pathologic feature of diabetic nephropathy. [1] [2] [3] [4] [5] Previous studies showed that intracellular oxidative stress, induced by hyperglycemia and angiotensin II (Ang II), is a causative factor in tissue damage associated with diabetes and hypertension. The activity of activator protein-1 (AP-1), an important transcription factor influenced by the cellular redox state, is increased in diabetic conditions. 6, 7 In addition, AP-1 has been implicated in transcriptional regulation of a wide range of genes participating in cell survival, proliferation, and apoptosis. [8] [9] [10] High glucose-and Ang II-induced activation of AP-1 triggers immediate early genes, resulting in early entry of G0-G1 phases and increased proliferation of MCs. 4, 5 After a limited early time period, however, cell proliferation and growth are arrested with the increased expression of TGF-b, which increases various mesangium matrix components. 11, 12 Recently, decoy technology was developed to reduce the trans-activity of transcription factors using synthetic double-stranded oligodeoxynucleotides (ODNs) containing the consensus-binding sequence of a transcription factor. [13] [14] [15] Several studies reported that introduction of decoy ODNs against their target transcription factors into specific cells downregulates the expression of several genes. Earlier results, including data from our own laboratory, indicate that AP-1 decoy ODN inhibits several downstream genes of transcription factor and cell proliferation in cultured vascular smooth muscle cells. 16 Although our previous investigations clearly demonstrated that treatment with AP-1 decoy ODNs effectively reduces several gene expressions containing the consensus binding sequence of AP-1 in vascular smooth muscle cells in vitro as well as in vivo, the effect of decoy ODN treatment in other cells and tissues have not been studied in detail.
We hypothesized from these findings that regulation of high glucose-and Ang II-induced AP-1 activity using AP-1 decoy ODN possibly modulates the initiation of MC proliferation and ECM production. To specifically inhibit AP-1 activation in cultured MCs, we have used circular dumbbell AP-1 decoy ODN molecules employed in a previous study to inhibit vascular smooth muscle cell proliferation. Here we explored the inhibitory effects of AP-1 decoy ODNs on MC proliferation and protein levels of various mesangium matrix components in vitro as well as in vivo.
Results
Effect of AP-1 decoy ODN on AP-1 activity
We transfected AP-1 decoy ODNs into rat MC to determine whether these ODNs affect the high glucoseand Ang II-induced DNA-binding activity of AP-1. Consistent with previous data, treatment with high glucose significantly increased the DNA-binding activity of AP-1, compared with binding at normal glucose concentrations in cultured rat MCs (Figure 1, Po0.01) . Similarly, the addition of Ang II (100 nM) led to an increase in the AP-1 activity (Po0.001). As expected, transfection of circular dumbbell AP-1 decoy ODN (CD-AP1 decoy) significantly attenuated the AP-1 DNAbinding activity induced by high glucose and Ang II (Po0.01) in a dose-dependent manner, whereas mutated AP-1 decoy ODN (M-AP1 decoy) did not affect the activity induced by high glucose and Ang II.
Effect of AP-1 decoy ODNs on promoter activity
The effect of AP-1 decoy ODNs on the promoter activity of ECM genes induced by high glucose and Ang II in cultured rat MCs was investigated. We employed reporter gene constructs, including pAP1(PMA)-TA-luc, pH5-luc (type I collagen a2 promoter construct), p3TP-lux (TGF-b1 promoter construct), and p800neo-luc (PAI-1 promoter construct), and AP-1 decoy ODN into rat MCs. Initially, we assessed the effect of AP-1 decoy ODNs on the promoter activity of reporter gene plasmids pAP1 (PMA)-TA-luc, which contain six tandem copies of the AP-1-binding sites in the promoter region and is used as positive control during treatment with high glucose and Ang II. As expected, cotransfection of CD-AP1 decoy markedly attenuated the upregulated luciferase gene expression induced by high glucose and Ang II ( Figure  2a , Po0.05), while the M-AP1 decoy did not affect this observed increase in luciferase activity. To determine the role of AP-1 decoy ODNs in high glucose-and Ang IIinduced upregulation of ECM gene promoter activity, we employed TGF-b1, type I collagen, and PAI-1 promoter luciferase plasmids (Figure 2b-d ). All these promoter plasmids displayed significant luciferase activity in the presence of high glucose and Ang II (Po0.05). As expected, these plasmids displayed decreased luciferase activity following treatment with CD-AP1 decoy, but not mutated decoy ODNs (Po0.01).
Effect of AP-1 decoy ODN on transcriptional expression
The effect of AP-1 decoy ODNs on the expression of ECM genes in cultured rat MCs was investigated. TGF-b is clearly linked to the development and progression of glomerulosclerosis through induction of several ECMrelated genes such as collagen and fibronectin. As shown in Figure 3 , both high glucose and Ang II stimulated TGF-b1 mRNA expression (Figure 3a , Po0.01) and downstream gene collagen expression (Figure 3b , Po0.01) in rat MCs. Transfection of CD-AP1 decoy, but not M-AP1 decoy, attenuated glucose-and Ang IIinduced expression of these genes (Po0.01). Transcriptional expression of TGF-b-target gene PAI-1, the major physiological inhibitor of tissue plasmanogen activator and urokinase, was also stimulated by high glucose (Figure 3c , Po0.01) and Ang II (Po0.001). Activation was significantly attenuated upon treatment with CD-AP1 decoy (Po0.01). These results indicate that direct inhibition of AP-1 trans-activity by AP-1 decoy ODNs reduces the expressions of TGF-b and downstream ECM genes.
Effect of AP-1 decoy ODNs on translational expression
To determine the effects of AP-1 decoy ODNs on mRNA and protein expressions of TGF-b1, type I collagen, and (Figure 4 ). Intracellular TGF-b1, type I collagen, and PAI-1 protein expressions were significantly induced by high glucose (Po0.05 compared to control) and Ang II (Po0.01 compared to control). Increased expression of these proteins was significantly inhibited by CD-AP1 decoy (Po0.05), but not M-AP1 decoy.
Effect of AP-1 decoy ODNs on mesangial cell proliferation
Compared with cells grown in normal glucose, cells incubated with high glucose for 48 h exhibited a significant increase in cell growth (Po0.05, Figure 5a ). After 3 days, there was no significant difference in cell growth in the presence of high glucose as compared to normal glucose. The decline in rat MC growth after 6 days culturing in normal glucose is possibly due to increased cell density.
Next, AP-1 decoy ODNs were assessed for their ability to inhibit rat MC growth (Figure 5b ). High glucose and Ang II stimulated the growth of cultured primary rat MCs (high glucose, Po0.05; Ang II, Po0.01 compared to control). Transfection of CD-AP1 decoy significantly inhibited cell growth stimulated by high glucose and Ang II (Po0.05 compared to high glucose; Po0.01 compared to Ang II).
Transfection efficiency of AP-1 decoy ODNs using the hemagglutinating virus of Japan (HVJ)-liposome method
To determine transfection efficiency, AP-1 decoy ODNs were labeled using the Label IT s fluorescein nucleic acid-labeling kit (Mirus). We intrarenally infused fluorescein-labeled AP-1 decoy ODN incorporated in HVJ liposomes, and the cellular uptake of fluorescence was determined by fluorescence microscopy and a spectrofluorometer (RF5301PC, Shimadzu, Japan) ( Figure 6 ). The fluorescence was strongly detected in tubular cells, and relatively weakly in glomeruli cells. The fluorescence Effect of AP-1 decoy ODNs on ECM production in the experimental rat kidney
The body weight, kidney weight, blood glucose levels, and serum concentrations of creatinine after 5, 10, and 15 days of AP-1 decoy ODN transfection were measured in the three groups of rats (Table 1) . Streptozoticin (STZ)-induced diabetic rat treated with either AP-1 decoy or mutated ODN displayed equivalently elevated blood glucose concentrations at each time period. Body weight was similarly reduced in rats treated with either wildtype AP-1 decoy or mutant decoy ODN (Po0.001 compared to control). Total kidney weight significantly increased in diabetic rats, compared to control rats (Po0.001). In contrast, the kidney weight in diabetic rats treated with CD-AP1 decoy was much lower than that in rats treated with M-AP1 decoy (Po0.05 compared to liposome only in each group). Serum creatinine concentration was much elevated in STZ-induced diabetic rat at 15 days than control rats (Po0.01). As expected, treatment of AP-1 decoy ODN decreased the rate of rise of creatinine (Po0.05 compared to STZinduced diabetic rats). Although the elevating and decreasing rates were significant statistically, they were clinically insignificant due to its normal ranging (normal range o133 mmol/l).
The effects of AP-1 decoy ODNs on MC proliferation and glomerular ECM production in vivo were evaluated by examining immunostaining of a-smooth muscle actin (an index of MC proliferation), TGF-b1, PAI-1, and ECM proteins (type I collagen and fibronectin). As expected, the diabetic state was accompanied by increased expression of proteins involved in MC proliferation and glomerular ECM production. As shown in Figure 7 , CD-AP1 decoy transfection attenuated the expressions of all of these proteins, but M-AP1 decoy transfection did not affect them.
Discussion
To test our hypothesis that AP-1 plays a critical role in the pathogenesis of mesangial cell proliferation and Although hyperglycemia and hypertension are suggested to contribute to the development of microvascular complications in patients with diabetes, only a few studies have focused on the direct effect of elevated glucose and Ang II concentrations on glomerular MCs. 4, 5, 11, 12 Here, we examined the effect of high glucose and Ang II on AP-1 DNA-binding activity in cultured rat MCs and ECM genes. Our data show that AP-1 DNAbinding and promoter activities of the ECM gene promoter luciferase constructs are significantly increased after treatment with high concentrations of glucose and Ang II in primary cultured rat MCs. Moreover, high glucose and Ang II stimulate endogenous mRNA expression of ECM genes and protein synthesis. CD-AP1 decoy, but not M-AP1 decoy, effectively attenuates rat MC proliferation and expression of ECM genes induced by high glucose and Ang II, consistent with the results of a promoter study. These data suggest that AP-1 trans-activity is crucial for high glucose-and Ang II-induced ECM synthesis.
Synthetic transcription factor decoys delivered into cells block binding of the transcription factor to its corresponding sites in target gene promoter regions, resulting in the inhibition of gene expression. [13] [14] [15] [16] To date, molecular therapeutic strategies using decoy ODN in glomerulonephritis have successfully focused on the direct effect of decoy ODN for transcription factor E2F or nuclear factor (NF)-kB. [17] [18] [19] [20] These transcription factors are related with cell cycle progression and inflammatory diseases after glomerular injury. Another transcription factor AP-1 binds to AP-1 consensus sequences present in numerous genes associated with cell-proliferative response and ECM production, such as TGF-b1, collagen, and PAI-1. 11, 12, [21] [22] [23] We reported previously that AP-1 decoy ODN abolishes the expression of several genes, including PAI-1 and TGF-b1, in other cell types. 15, 24 In this study, we employed circular dumbbell decoy ODN instead of phosphorothioate decoy ODN to overcome the disadvantages of the chemically modified form. 16, 25 Moreover, to maximize the AP-1 decoy ODN delivery efficiency in vivo, we delivered these ODNs with HVJ liposomes via the intra-arterial route in experimental animal models. 17 AP-1 decoy ODNs specifically suppressed the high glucose-and Ang II-induced TGFb1 and ECM gene expression in cultured rat glomerular Our data clearly demonstrated that AP-1 is a key transcription factor mediating mesangial cell proliferation and ECM gene expression involved in glomerular expansion. This new molecular strategy, using CD-AP1 decoy with highly effective HVJ-liposome gene-delivery technique, could represent a powerful investigative and potentially therapeutic strategy in the prevention and treatment of diabetic nephropathy.
Materials and methods

Animals
Male Sprague-Dawley (SD) rats, 9-10-week old, weighing between 280 and 320 g were used. All procedures were in accordance with the institutional guidelines for animal research.
Cell isolation and culture
Rat glomerular mesangial cells (RMCs) were obtained from isolated, collagenase-treated rat glomeruli. In brief, glomeruli were harvested from 100 g male SD rats by filteration with ice-cold phosphate buffer through 150, 80, and 85 mm nylon meshes. Those retained on the sieve were collected, washed by centrifugation (41C, 800 rpm), and incubated with 250 U/ml collagenase (type I) for 30 min at 371C under constant, gentle shaking. RMCs were plated on plastic tissue culture dishes in DMEM with 20% FBS. The cell medium was left untouched for 4 days and then changed every other day until confluence. These cells were characterized by typical stellate morphology, positive staining for desmin and vimentin. All assays were performed on cells at passages three to seven.
Construction of CDODN
The sequences of CD-AP1 decoy and M-AP1 decoy used are as follows: 16 CD-AP1 decoy (note: consensus sequences are underlined), 5 0 -GGATCCATGACTCA GAAGACGACACACGTCTTCTGAGTCAT-3 0 ; M-AP1 decoy, 5 0 -GGATCCAAATCTCAGAAGACGACACAC GTCTTCT-GAGATTT-3 0 . ODNs were annealed for 2 h at a decreasing temperature (80 to 251C). One unit of T4 DNA ligase was added to the mixture and incubated for 24 h at 161C to generate a covalently ligated dumbbellshaped decoy ODN molecule. CD-AP1 decoy consists of two loops and one stem, containing two AP-1 consensus sequences in tandem.
In vitro gene transfer
Cells were fed with fresh culture medium the day before decoy was added and washed twice with Opti-MEM (Gibco BRL), prior to the experiment. Next, cells were transfected with 100 nM of AP-1 decoy ODN combined with LipofectAMINE Plust (molar ratio; DNA:lipid ¼ 1:3) (Gibco BRL). The decoy ODN:lipid mixture was added dropwise to cells, according to the manufacturer's instructions. Cells were incubated at 371C for 5 h. After the addition of fresh medium containing 10% FBS, cells were maintained in a CO 2 incubator until use.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from VSMCs as described previously. In brief, DNA probes, such as those for AP-1 and mutated ODN, were labeled using [g- AP-1 decoy treatment in mesangial cells JD Ahn et al end-labeling, 32 P-labeled ODNs were purified using a NAP-5 column. Protein-DNA-binding reactions were performed at room temperature for 20 min in a volume of 20 ml. Reaction mixtures contained 6 mg nuclear extract, 100 mg/ml poly dI:dC, 10 mM Tris/HCl (pH 7.5), 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 1 mM MgCl 2 , 4% glycerol, and 60 000 cpm 32 P-labeled primer DNA. After incubation, samples were loaded onto 4% native polyacrylamide gels in 0.5 Â Tris-borate-EDTA buffer, and run at 150 V for 2 h. Gels were dried and visualized by autoradiography. The experimental conditions for competition studies were identical, except that appropriate competitor ODNs were added to the reaction mixtures at 50-100-fold molar excess before adding nuclear extracts.
Luciferase assay
Promoter luciferase constructs including pAP1(PMA)-TA-luc (AP-1-positive control promoter construct), pH5-luc (type I collagen a2 promoter construct), p3TP-lux (TGF-b1 promoter construct), and p800neo-luc (PAI-1 promoter construct) were employed to investigate the effects of AP-1 decoy ODN on promoter activity. To analyse luciferase expression, cells were washed twice with PBS and lysed with 200 ml of 1 Â Reporter lysis buffer (Promega, Madison, WI, USA). Each lysate (50 ml) was examined for luciferase activity.
Northern blot analysis
Radiolabeled probes used for Northern blot analysis were prepared by the random primer labeling method with [a-32 P]dCTP, using a random primer labeling kit (Amersham, Arlington Heights, IL, USA). After the labeling reaction, the radiolabeled probes were purified on an NAP-5 column (Pharmacia, Uppsala, Sweden). Total RNA for Northern analysis was extracted by RNeasy RNA extraction kit (Qiagen, Hilden, Germany). A measure of 10 mg of total RNA was applied to a 1% formaldehyde-agarose gel and transferred to a nylon membrane. The nylon membrane was hybridized in Express Hybt solution at 651C for 2 h with a radiolabeled cDNA probe, and washed according to the manufacturer's instructions. The membrane was exposed to X-ray film for 24-48 h, and the mRNA expression was quantified with densitometric analysis. Loading differences were normalized using an 18s rRNA cDNA probe.
Cell lysate, protein quantification, and Western blot analysis
Cells were washed twice with PBS and suspended in IPH lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 0.5% NP40, 100 mM PMSF, leupeptin 1 mg/ml, apronitin 1 mg/ml, 1 M DTT). Cells were extracted at 41C for 30 min. After centrifugation at 12 000 rpm for 20 min, the supernatant was obtained as cell lysate. Protein quantification was performed using a Biorad protein assay system (Biorad Laboratories). Cell lysates (30 mg/ lane) were electrophoresed on 10% SDS-PAGE and transferred to an Immobilon-P-membrane. The membrane was allowed to react with anti-TGF-b1 polyclonal antibody (Cell sciences), anticollagen type I polyclonal antibody, and anti-PAI-1 polyclonal antibody (Santa Cruz). Antibodies were detected by horseradish peroxidase-linked secondary antibody using the ECL Western blotting detection system, as specified by the manufacturer.
Effect of decoy ODN on rat MC growth
Rat MCs cultured in normal glucose concentration (5.5 mM) were removed from culture flasks by incubating with trypsine/EDTA. Equal numbers of cells were seeded onto tissue culture plates. At 20-50% confluence, MCs were rendered quiescent by incubation for 24 h in either insulin-or serum-free growth medium. Cells were then exposed to either normal glucose or high glucose (25 mM) containing 0.1% serum for 8 days. Following incubation, an index of cell proliferation was determined with a WST cell counting kit (Wako, Osaka, Japan). To evaluate the effect of AP-1 decoy ODNs on RMC proliferation, LipofectAMINE Plus:decoy ODN (100 nM decoy ODN) was added to the wells, and cells were incubated at 371C for a further 5 h . After 48 h, cell proliferation was determined with a WST cell counting kit.
Preparation of HVJ liposome
HVJ liposomes were prepared as described previously. 16 Briefly, cholesterol, dioleoylphosphatidylethanolamine, phosphatidylcholine, sphingomyeline, and phosphatidylserine were mixed in a molar ratio of 50:13.3:13.3:13.3:10. The lipid mixture was deposited on a flask side by chloroform evaporation. Dried lipid was hydrated in 200 ml balanced salt solution (BSS; 137 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6) containing ODN. Liposomes were prepared by shaking and filtration. Purified HVJ (Z strain) was inactivated by UV irradiation for 3 min immediately before use. The liposome suspension was mixed with HVJ in a total volume of 2 ml BSS. The mixture was incubated at 41C for 5 min, followed by 30 min incubation with gentle shaking at 371C. Free HVJ was removed from HVJ liposomes by sucrose density gradient centrifugation. The top layer of the sucrose gradient was collected for use.
Experimental diabetic animal model and in vivo transfection
Diabetes was induced in 9-10-week old male SD rats by two consecutive intraperitoneal injections of streptozotocin (100 mg/kg body weight, Sigma). Following detection of high blood glucose (4250 mg/dl), rats were anesthetized with sodium pentobarbital (50 mg/kg body weight), and the left renal artery of each animal was surgically exposed. A cannula was introduced into the left renal artery via the aorta. The proximal segment of the renal artery was transiently ligated and HVJliposome complex was infused into the renal artery over 5 min. Upon completion, the infusion cannula was removed and blood flow to the kidney was restored by release of ligatures, and the wound was then closed.
Histological analysis
Following transfection, rats were killed and kidneys were perfusion-fixed with 4% paraformaldehyde. For immunohistochemistry, sections were incubated with anti-TGF-b1, PAI-1, fibronectin, type I collagen (SantaCruz Biotechnology), and a-smooth muscle actin 
Statistical analyses
Results are expressed as mean7SEM. Analysis of variance was performed with Duncan's test and used to determine significant differences in multiple comparisons. Data were taken as statistically significant at Po0.05. All experiments were performed at least three times.
